Pre-existing T cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC) Meeting Abstract
| Authors: | Mariathasan, S.; Turley, S. J.; Nickles, D.; Wang, Y.; Kadel, E. E. 3rd; Koeppen, H.; Yuen, K.; Castiglioni, A.; Astarita, J. L.; Cubas, R.; Jhunjhunwala, S.; Banchereau, R.; Yang, Y.; Guan, Y.; Chalouni, C.; Ziai, J.; Şenbabaoğlu, Y.; Lianoglou, S.; van der Heijden, M.; Loriot, Y.; Rosenberg, J.; Fong, L.; Mellman, I.; Chen, D. S.; Green, M.; Derleth, C.; Fine, G. D.; Hegde, P. S.; Bourgon, R.; Powles, T. |
| Abstract Title: | Pre-existing T cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC) |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 86 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0289-3 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P13 |
